Remember meForgot password?
    Log in with Twitter
Press Release

Jul 12, 2018 15:10 UTC

Frontotemporal Lobe Dementia - 2018-2028 -

DUBLIN--(Business Wire)--The "Epiomic Epidemiology Series: Frontotemporal Lobe Dementia Forecast In 19 Major Markets 2018-2028" report has been added to's offering.

This report provides the current prevalent population for FTD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort.

Along with the current prevalence, the report provides a breakdown of the sub-group classifications of the disease, disease origin and tau protein mutations in the FTD patient population. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of FTD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for FTD include:

  • Dementia and cognitive disorders
  • Speech and semantic problems
  • Limb/muscle weakness and rigidity
  • Behavioural disorders
  • Appetite changes

Reasons to buy

  • Able to quantify patient populations in global FTD market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of FTD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on FTD prevalent population.
  • Examination of the prevalence for different causative protein mutations in FTD.
  • Identify sub-populations within FTD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of FTD patients.

Key Topics Covered:

  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Comorbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for FTD
  • Features of FTD Patients
  • Classification
  • Genetic Background
  • Neurological/Behavioural Symptoms
  • Comorbidities of FTD Patients
  • Other Services & Solutions
  • Online Epidemiology Databases
  • Online Pharmaceutical Pricing Database

For more information about this report visit
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Latest News
Top News